Acneiform Skin Lesions Associated With Cetuximab Therapy: Report of Two Cases

Yıl 2010, Cilt: 27 Sayı: 3, - , 09.02.2011

Özlem Yılmaz Müge Güler Özden Fatma Aydın Nilgün Şentürk Tayyar Cantürk Ahmet Yaşar Turanlı

Öz

Abstract
Cetuximab, is an IgG1 chimeric monoclonal antibody type of epidermal growth factor receptor (EGFR). It is most commonly prescribed for metastatic colorectal cancer, administered alone or in combination with irinotecan-based chemotherapy regimens (Lee JE, et al., 2008; Segaert S, et al., 2005; Segaert S, Cutsem EV, 2005; Scope A, et al., 2009). Acneiform eruption is the most common adverse effect with 80% of incidence (Lee JE, et al., 2008; Segaert S, Cutsem EV, 2005). We report two cases of severe acneiform eruption induced by cetuximab with metastatic colorectal cancer.

Key words: Cetuximab, acneiform eruption, colorectal cancer, irinotecan, chemotherapy, side effect.



CETUXİMAB TEDAVİSİNE BAĞLI AKNEİFORM DERİ LEZYONLARI:
İKİ OLGU

Cetuximab, epidermal büyüme faktörü reseptörünün, IgG1 tipindeki şimerik monoklonal antikorudur. Metastatik kolorektal kanserlerin kemoterapi rejimlerinde, tek başına veya irinotekan ile kombine olarak kullanılmaktadır (Lee JE, et al., 2008; Segaert S, et al., 2005; Segaert S, Cutsem EV, 2005; Scope A, et al., 2009). Akneiform erüpsiyon, % 80 oran ile en sık görülen yan etkisidir(Lee JE, et al., 2008; Segaert S, Cutsem EV, 2005). Bu makalede metastatik kolorektal kanserli hastada cetuximab ile oluşan yaygın akneiform erupsiyonu olan iki olgu bildirdik.

Anahtar kelimeler: Cetucimab, akneiform erüpsiyon, kolorektal kanser, irinotekan, kemoterapi, yan etki.

Anahtar Kelimeler

Cetuximab

Kaynakça

• Gutzmer, R., Werfel, T., Mao, R., Kapp, A., Elsner, J., 2005. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br. J. Dermatol. 153,842–868
• Lee, J.E., Lee, S.J., Lee, J.H., Lee, K.H., 2008. Severe Acneiform Eruption Induced by Cetuximab (Erbitux). Yonsei Med. J. 49, 851–852.
• Segaert, S., Cutsem, E.V., 2005. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncology. 16, 1425–1433.
• Segaert, S., Tabernero, J., Chosidow, O., 2005. The management of skin reactions in cancer patients receving epidermal growth factor receptor targeted therapies. JDDG. 3, 599- 606
• Suh, K.Y., Kindler, H.L., Medenica, M., Lacouture, M., 2006. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br. J. Dermatol. 154,177–204
• Scope, A., Lieb, J.A., Dusza, S.W., 2009. 2009. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption. J. Am. Acad. Dermatol. 61,614- 620.
• Vaccaro, M., Pollicino, A., Barbuzza, O., Guarneri, B., 2008. Trichomegaly of the eyelashes following treatment with cetuximab. Clin. Exp. Dermatol. 34, 402–425